Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration

Science Signaling

Volumn 7, Issue 345, 2014, Pages ra92-

  Phesse, Toby J ^a,b,c   Buchert, Michael ^a,b,c   Stuart, Emma ^a,b,c   Flanagan, Dustin J ^c,d,e   Faux, Maree ^a,b,c   Afshar Sterle, Shoukat ^a,b,c   Walker, Francesca ^a,b,c   Zhang, Hui Hua ^a,b,c   Nowell, Cameron J ^a,b,c   Jorissen, Robert ^a,b,c   Tan, Chin Wee ^a,b,c   Hirokawa, Yumiko ^a,b,c   Eissmann, Moritz F ^a,b,c   Poh, Ashleigh R ^a,b,c   Malaterre, Jordane ^c,f   Pearson, Helen B ^c,f   Kirsch, David G ^g   Provero, Paolo ^h   Poli, Valeria ^h   Ramsay, Robert G ^c,f   Sieber, Oliver ^a,b,c   Burgess, Antony W ^a,b,c   Huszar, Dennis ⁱ   Vincan, Elizabeth ^c,d,e   Ernst, Matthias ^a,b,c   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; BMI1 PROTEIN; CYTOKINE; GLYCOPROTEIN GP 130; JANUS KINASE; PROTEIN P16; PROTEIN P21; STAT3 PROTEIN; WNT PROTEIN; BMI1 PROTEIN, MOUSE; IL6ST PROTEIN, MOUSE; JAK1 PROTEIN, MOUSE; JANUS KINASE 1; LUCIFERASE; ONCOPROTEIN; PRIMER DNA; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENE REPRESSION; HETEROZYGOSITY LOSS; HOMEOSTASIS; INTESTINE CANCER; INTESTINE CRYPT; IRRADIATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; METABOLISM; PHYSIOLOGY; REGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; COLONIC NEOPLASMS; CYTOKINE RECEPTOR GP130; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HISTOLOGICAL TECHNIQUES; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; JANUS KINASE 1; LUCIFERASES; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; REGENERATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; WNT SIGNALING PATHWAY;

EID: 84907879855     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005411     Document Type: Article

References (68)

1. H. Clevers, The intestinal crypt, a prototype stem cell compartment. Cell 154, 274-284 (2013).
2. H. Ireland, R. Kemp, C. Houghton, L. Howard, A. R. Clarke, O. J. Sansom, D. J. Winton, Inducible cre-mediated control of gene expression in the murine gastrointestinal tract: Effect of loss of b-catenin. Gastroenterology 126, 1236-1246 (2004).
3. V. Muncan, O. J. Sansom, L. Tertoolen, T. J. Phesse, H. Begthel, E. Sancho, A. M. Cole, A. Gregorieff, I. M. de Alboran, H. Clevers, A. R. Clarke, Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol. Cell. Biol. 26, 8418-8426 (2006).
4. G. H. Ashton, J. P.Morton, K. Myant, T. J. Phesse,R.A. Ridgway, V. Marsh, J. A. Wilkins, D. Athineos, V. Muncan, R. Kemp, K. Neufeld, H. Clevers, V. Brunton, D. J. Winton, X. Wang, R. C. Sears, A. R. Clarke, M. C. Frame, O. J. Sansom, Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev. Cell 19, 259-269 (2010).
5. H. Clevers, R. Nusse, Wnt/b-catenin signaling and disease. Cell 149, 1192-1205 (2012).
6. J. N. Anastas, R. T. Moon, WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013).
7. O. J. Sansom, V. S. Meniel, V. Muncan, T. J. Phesse, J. A.Wilkins, K. R. Reed, J. K. Vass, D. Athineos, H. Clevers, A. R. Clarke, Myc deletion rescues Apc deficiency in the small intestine. Nature 446, 676-679 (2007).
8. L. Soucek, J. Whitfield, C. P. Martins, A. J. Finch, D. J. Murphy, N. M. Sodir, A. N. Karnezis, L. B. Swigart, S. Nasi, G. I. Evan, Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008).
9. A. Jarnicki, T. Putoczki, M. Ernst, Stat3: Linking inflammation to epithelial cancer- More than a "gut" feeling? Cell Div. 5, 14 (2010).
10. M. Ernst, T.Putoczki,Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers. Clin. Cancer Res. 10.1158/1078-0432.CCR-13-2492 (2014).
11. T. L. Putoczki, S. Thiem, A. Loving, R. A. Busuttil, N. J. Wilson, P. K. Ziegler, P. M. Nguyen, A. Preaudet, R. Farid, K. M. Edwards, Y. Boglev, R. B. Luwor, A. Jarnicki, D. Horst, A. Boussioutas, J. K. Heath, O. M. Sieber, I. Pleines, B. T. Kile, A. Nash, F. R. Greten, B. S. McKenzie, M. Ernst, Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24, 257-271 (2013).
12. N. C. Tebbutt, A. S. Giraud, M. Inglese, B. Jenkins, P.Waring, F. J. Clay, S. Malki, B. M. Alderman, D. Grail, F. Hollande, J. K. Heath, M. Ernst, Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8, 1089-1097 (2002).
13. J. Bollrath, T. J. Phesse, V. A. von Burstin, T. Putoczki, M. Bennecke, T. Bateman, T. Nebelsiek, T. Lundgren-May, O. Canli, S. Schwitalla, V. Matthews, R. M. Schmid, T. Kirchner, M. C. Arkan, M. Ernst, F. R. Greten, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
14. T. Kusaba, T. Nakayama, K. Yamazumi, Y. Yakata, A. Yoshizaki, T. Nagayasu, I. Sekine, Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J. Clin. Pathol. 58, 833-838 (2005).
15. K. Takeda, K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto, N. Yoshida, T. Kishimoto, S. Akira, Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 94, 3801-3804 (1997).
16. M. Hedvat, D. Huszar, A. Herrmann, J. M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C. M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z. A. Cao, H. Yu, R. Jove, M. Zinda, The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
17. T. J. Phesse, L. Parry, K. R. Reed, K. B. Ewan, T. C. Dale, O. J. Sansom, A. R. Clarke, Deficiency of Mbd2 attenuates Wnt signaling. Mol. Cell. Biol. 28, 6094-6103 (2008).
18. T. Sato, J. H. van Es, H. J. Snippert, D. E. Stange, R. G. Vries, M. van den Born, N. Barker, N. F. Shroyer, M. van de Wetering, H. Clevers, Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418 (2011).
19. K. Siddiquee, S. Zhang, W. C. Guida, M. A. Blaskovich, B. Greedy, H. R. Lawrence, M. L. Yip, R. Jove, M. M. McLaughlin, N. J. Lawrence, S. M. Sebti, J. Turkson, Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 104, 7391-7396 (2007).
20. L. K. Su, K.W. Kinzler, B. Vogelstein, A. C. Preisinger, A. R. Moser, C. Luongo, K. A. Gould, W. F. Dove, Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670 (1992).
21. M. Musteanu, L. Blaas, M. Mair, M. Schlederer, M. Bilban, S. Tauber, H. Esterbauer, M. Mueller, E. Casanova, L. Kenner, V. Poli, R. Eferl, Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice. Gastroenterology 138, 1003-1011.e5 (2010).
22. E. A. McLellan, R. P. Bird, Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res. 48, 6187-6192 (1988).
23. B. J. Shields, C. Hauser, P. E. Bukczynska, N. W. Court, T. Tiganis, DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 14, 166-179 (2008).
24. N. Barker, R. A. Ridgway, J. H. van Es, M. van de Wetering, H. Begthel, M. van den Born, E. Danenberg, A. R. Clarke, O. J. Sansom, H. Clevers, Crypt stem cells as the cells-oforigin of intestinal cancer. Nature 457, 608-611 (2009).
25. H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
26. S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio, J. V. Catalano, M. Deininger, C. Miller, R. T. Silver, M. Talpaz, E. F.Winton, J. H. Harvey Jr., M. O. Arcasoy, E. Hexner, R. M. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson-Viitanen, I. L. Koumenis, W. Sun, V. Sandor, H. M. Kantarjian, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807 (2012).
27. Y. Hong, T. Downey, K. W. Eu, P. K. Koh, P. Y. Cheah, A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin. Exp. Metastasis 27, 83-90 (2010).
28. M. Skrzypczak, K. Goryca, T. Rubel, A. Paziewska, M. Mikula, D. Jarosz, J. Pachlewski, J. Oledzki, J. Ostrowski, Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLOS One 5, e13091 (2010).
29. W. de Lau, N. Barker, T. Y. Low, B. K. Koo, V. S. Li, H. Teunissen, P. Kujala, A. Haegebarth, P. J. Peters, M. van de Wetering, D. E. Stange, J. E. van Es, D. Guardavaccaro, R. B. Schasfoort, Y. Mohri, K. Nishimori, S. Mohammed, A. J. Heck, H. Clevers, Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293-297 (2011).
30. Y. M. Oh, J. K. Kim, Y. Choi, S. Choi, J. Y. Yoo, Prediction and experimental validation of novel STAT3 target genes in human cancer cells. PLOS One 4, e6911 (2009).
31. M. Snyder, X. Y. Huang, J. J. Zhang, Identification of novel direct Stat3 target genes for control of growth and differentiation. J. Biol. Chem. 283, 3791-3798 (2008).
32. A. P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M. Kerr, V. Poli, Mutational switch of an IL-6 response to an interferon-glike response. Proc. Natl. Acad. Sci. U.S.A. 99, 8043-8047 (2002).
33. M. C. Faux, J. L. Ross, C.Meeker, T. Johns, H. Ji, R. J. Simpson, M. J. Layton, A.W. Burgess, Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J. Cell Sci. 117, 427-439 (2004).
34. R. Radinsky, S. Risin, D. Fan, Z. Dong, D. Bielenberg, C. D. Bucana, I. J. Fidler, Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1, 19-31 (1995).
35. J. B. Cordero, R. K. Stefanatos, K. Myant, M. Vidal, O. J. Sansom, Non-autonomous crosstalk between the Jak/Stat and Egfr pathways mediates Apc1-driven intestinal stem cell hyperplasia in the Drosophila adult midgut. Development 139, 4524-4535 (2012).
36. J. R. Matthews, O. J. Sansom, A. R. Clarke, Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ. 18, 1934-1943 (2011).
37. J. F. McManus, Histological demonstration of mucin after periodic acid. Nature 158, 202 (1946).
38. T. Peeters, G. Vantrappen, The Paneth cell: A source of intestinal lysozyme. Gut 16, 553-558 (1975).
39. A. P. Bracken, D. Kleine-Kohlbrecher, N. Dietrich, D. Pasini, G. Gargiulo, C. Beekman, K. Theilgaard-Monch, S. Minucci, B. T. Porse, J. C. Marine, K. H. Hansen, K. Helin, The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530 (2007).
40. F. Vallania, D. Schiavone, S. Dewilde, E. Pupo, S. Garbay, R. Calogero, M. Pontoglio, P. Provero, V. Poli, Genome-wide discovery of functional transcription factor binding sites by comparative genomics: The case of Stat3. Proc. Natl. Acad. Sci. U.S.A. 106, 5117-5122 (2009).
41. M. Ernst, M. Najdovska, D. Grail, T. Lundgren-May, M. Buchert, H. Tye, V. B. Matthews, J. Armes, P. S. Bhathal, N. R. Hughes, E. G. Marcusson, J. G. Karras, S. Na, J. D. Sedgwick, P. J. Hertzog, B. J. Jenkins, STAT3 and STAT1 mediate IL-11-dependent and inflammationassociated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118, 1727-1738 (2008).
42. K. Brocke-Heidrich, B. Ge, H. Cvijic, G. Pfeifer, D. Loffler, C. Henze, T. W. McKeithan, F. Horn, BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25, 7297-7304 (2006).
43. O. J. Sansom, V. Meniel, J. A. Wilkins, A. M. Cole, K. A. Oien, V. Marsh, T. J. Jamieson, C. Guerra, G. H. Ashton, M. Barbacid, A. R. Clarke, Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 14122-14127 (2006).
44. M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé,W. G. Kerr, R. Jove, D. Pardoll, H. Yu, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005).
45. O. J. Sansom, K. R. Reed, A. J. Hayes, H. Ireland, H. Brinkmann, I. P. Newton, E. Batlle, P. Simon-Assmann, H. Clevers, I. S. Nathke, A. R. Clarke, D. J. Winton, Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18, 1385-1390 (2004).
46. B. J. Jenkins, D. Grail, T. Nheu, M. Najdovska, B. Wang, P. Waring, M. Inglese, R. M. McLoughlin, S. A. Jones, N. Topley, H. Baumann, L. M. Judd, A. S. Giraud, A. Boussioutas, H. J. Zhu, M. Ernst, Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11, 845-852 (2005).
47. Y. Q. Tong, B. Liu, H. Y. Zheng, Y. J. He, J. Gu, F. Li, Y. Li, Overexpression of BMI-1 is associated with poor prognosis in cervical cancer. Asia Pac. J. Clin. Oncol. 8, e55-e62 (2012).
48. T. Yin, H. Wei, Z. Leng, Z. Yang, S. Gou, H. Wu, G. Zhao, X. Hu, C. Wang, Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy 57, 488-496 (2011).
49. D. W. Li, H. M. Tang, J. W. Fan, D. W. Yan, C. Z. Zhou, S. X. Li, X. L. Wang, Z. H. Peng, Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J. Cancer Res. Clin. Oncol. 136, 997-1006 (2010).
50. J. Du, Y. Li, J. Li, J. Zheng, Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med. Oncol. 27, 1273-1276 (2010).
51. C. A. Fasano, J. T. Dimos, N. B. Ivanova, N. Lowry, I. R. Lemischka, S. Temple, shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC selfrenewal during development. Cell Stem Cell 1, 87-99 (2007).
52. A. Kreso, P. van Galen, N. M. Pedley, E. Lima-Fernandes, C. Frelin, T. Davis, L. Cao, R. Baiazitov, W. Du, N. Sydorenko, Y. C. Moon, L. Gibson, Y. Wang, C. Leung, N. N. Iscove, C. H. Arrowsmith, E. Szentgyorgyi, S. Gallinger, J. E. Dick, C. A. O'Brien, Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29-36 (2014).
53. E. Sangiorgi, M. R. Capecchi, Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 40, 915-920 (2008).
54. N. Barker, Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 15, 19-33 (2014).
55. R. M. Logan, A. M. Stringer, J. M. Bowen, A. S. Yeoh, R. J. Gibson, S. T. Sonis, D. M. Keefe, The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat. Rev. 33, 448-460 (2007).
56. S. Schwitalla, A. A. Fingerle, P. Cammareri, T. Nebelsiek, S. I. Goktuna, P. K. Ziegler, O. Canli, J. Heijmans, D. J. Huels, G. Moreaux, R. A. Rupec, M. Gerhard, R. Schmid, N. Barker, H. Clevers, R. Lang, J. Neumann, T. Kirchner, M. M. Taketo, G. R. van den Brink, O. J. Sansom, M. C. Arkan, F. R. Greten, Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013).
57. M. Ernst, M. Inglese, P. Waring, I. K. Campbell, S. Bao, F. J. Clay, W. S. Alexander, I. P. Wicks, D. M. Tarlinton, U. Novak, J. K. Heath, A. R. Dunn, Defective gp130- mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J. Exp. Med. 194, 189-203 (2001).
58. T. Morikawa, Y. Baba, M. Yamauchi, A. Kuchiba, K. Nosho, K. Shima, N. Tanaka, C. Huttenhower, D. A. Frank, C. S. Fuchs, S. Ogino, STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 17, 1452-1462 (2011).
59. A. M. Cole, R. A. Ridgway, S. E. Derkits, L. Parry, N. Barker, H. Clevers, A. R. Clarke, O. J. Sansom, p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. EMBO Mol. Med. 2, 472-486 (2010).
60. T. Lau, E. Chan, M. Callow, J. Waaler, J. Boggs, R. A. Blake, S. Magnuson, A. Sambrone, M. Schutten, R. Firestein, O. Machon, V. Korinek, E. Choo, D. Diaz, M. Merchant, P. Polakis, D. D. Holsworth, S. Krauss, M. Costa, A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 73, 3132-3144 (2013).
61. T. Fujishita, K. Aoki, H. A. Lane, M. Aoki, M. M. Taketo, Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcD716 mice. Proc. Natl. Acad. Sci. U.S.A. 105, 13544-13549 (2008).
62. J. H. van Es, M. E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. Robine, D. J. Winton, F. Radtke, H. Clevers, Notch/g-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
63. J. R. Strosberg, T. Yeatman, J. Weber, D. Coppola, M. J. Schell, G. Han, K. Almhanna, R. Kim, T. Valone, H. Jump, D. Sullivan, A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer 48, 997-1003 (2012).
64. J. Rodon, R. Dienstmann, V. Serra, J. Tabernero, Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153 (2013).
65. S. G. Tangye, M. C. Cook, D. A. Fulcher, Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J. Immunol. 182, 21-28 (2009).
66. T. Alonzi, D. Maritano, B. Gorgoni, G. Rizzuto, C. Libert, V. Poli, Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene activation in the liver. Mol. Cell. Biol. 21, 1621-1632 (2001).
67. N. M. van der Lugt, J. Domen, K. Linders, M. van Roon, E. Robanus-Maandag, H. te Riele, M. van der Valk, J. Deschamps, M. Sofroniew, M. van Lohuizen, A. Berns, Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8, 757-769 (1994).
68. K. J. Livak, T. D. Schmittgen, Analysis of relative gene expression data using realtime quantitative PCR and the 2-DDCT method. Methods 25, 402-408 (2001).